1. Home
  2. CIFR vs BLCO Comparison

CIFR vs BLCO Comparison

Compare CIFR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CIFR

Cipher Mining Inc.

HOLD

Current Price

$15.17

Market Cap

5.7B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.58

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIFR
BLCO
Founded
2021
1853
Country
United States
Canada
Employees
66
N/A
Industry
Investment Bankers/Brokers/Service
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CIFR
BLCO
Price
$15.17
$16.58
Analyst Decision
Strong Buy
Buy
Analyst Count
11
12
Target Price
$24.27
$18.55
AVG Volume (30 Days)
19.8M
439.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
$39.59
$8.61
Revenue Next Year
$192.90
$5.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$1.86
$10.45
52 Week High
$25.52
$18.92

Technical Indicators

Market Signals
Indicator
CIFR
BLCO
Relative Strength Index (RSI) 49.49 41.63
Support Level $15.04 $16.35
Resistance Level $15.54 $16.81
Average True Range (ATR) 1.06 0.49
MACD 0.03 -0.19
Stochastic Oscillator 55.74 20.57

Price Performance

Historical Comparison
CIFR
BLCO

About CIFR Cipher Mining Inc.

Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: